ArchiveFebruary 2017

Tabalumab (LY 2127399) Trial in 243 people in 63 Centres. Where you involved? what Happened?

You said  “I believe patients participating in trials have the right to be informed about the trial results”. I said “I agree with you…are any of the readers, people who participated in this Eli Lilly MS trial. Were you informed of the results? (NCT00882999)” However, should we have to be detectives? In this case, we have not proof that people were harmed, but...

Modifiable risk factors in MS – help yourself

Modifiable Risk Factors in the Progression of Multiple Sclerosis: A Systematic Review of the Epidemiology and Treatment [Internet]. Editors Hempel S, Fu N, Estrada E, Chen A, Miake-Lye I, Beroes J, Miles J, Shanman R, Shekelle P. Source Washington (DC): Department of Veterans Affairs (US); 2015 Dec. VA Evidence-based Synthesis Program Reports. Excerpt Multiple sclerosis (MS) is the most common...

What’s Happening with the Clinical Trial Data

As soon as rituximab and then Ocrelizumab was found to inhibit relapsing MS, companies began the hunt for “me-toos” to do the same thing. Ocreliziumab depletes CD20 B cells and blocks relapses, so it gets rid of memory B cells, but not the earliest of B cells or the antibody forming plasma cells. Unless you know what CD20-B cell depletion is doing, getting rid of the all B cells may...

ACTRIMS 2017 further points to Memory B cells

This week ACTRIMS has been going. The academics have been microbioming and even got salt in the act as salt affects gut bacteria, but in terms of pharma news this is a poor companion to ECTRIMS and the AAN. However, a couple of weeks ago we suggested that drugs that inhibit MS, target memory B cells.  Have a read (click on the link below) The data published with dimethyl fumarate was not so...

Animals in Research

Why do we talk about Animal Research on the Blog? Signatories (including Queen Mary and 111 other signatories) to the Concordat of animals in research (Click here) have agreed to be more open about their use of animals in research, and to abide by the following four commitments. Commitment 1: We will be clear about when, how and why we use animals in research Commitment 2: We will...

Secondary Progressive EAE. Is it the astrocyte?

Some body asked me to comment on this paper. Rothhammer V, Kenison JE, Tjon E, Takenaka MC, de Lima KA, Borucki DM, Chao CC, Wilz A, Blain M, Healy L, Antel J, Quintana FJ. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation. Proc Natl Acad Sci U S A. 2017;114(8):2012-2017. Multiple sclerosis (MS) is an autoimmune...

Dodgy EAE experiments means more wasted animals

Yesterday we say that there was a desire to do multi centre animal studies. We said if you do rubbishy animal experiments, you get rubbish. A well planned and undertaken experiment can mean more than ten rubbish experiments. The funny thing is that the suggestion of mutli-centre animal trails was published in the Journal Nature . This is a bit rich, because whilst we want to get our papers...

No publication without reproduction

Mogil JS & Macleod MRNo publication without confirmation This says “Concern over the reliability of published biomedical results grows unabated. Frustration with this ‘reproducibility crisis’ is felt by everyone pursuing new disease treatments: from clinicians and would-be drug developers who want solid foundations on which animal studies are based”. ...

HSCT activity in Progressive MS

Paolo A. Muraro, et al.Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol 2017 Question:  What are the long-term outcomes after autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis? Findings:  In this multicenter cohort study of 281 patients with predominantly progressive forms of multiple...

Guest Post MSBaseGold: Comparisons of DMT

Today we are delighted to have another Guest post from Tomas Kalincik from University of Melbourne, Australia, please see his Biography on his previous post. Kalincik et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017 Feb 10. pii: S1474-4422(17)30007-8...

Translate

Categories

Recent Posts

Recent Comments

Archives